Therefore, GRMS-55 may be considered a safer and more efficient alternative to PDE4-selective inhibitors and a promising drug candidate for the treatment of AIH as it possesses anti-inflammatory activity and does not cause side effects related to the inhibition of the PDE4D subtype. The gene discussed is PDE4A; the disease is autoimmune hepatitis.